203 related articles for article (PubMed ID: 7805371)
21. A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
Walling M
Contraception; 1992 Oct; 46(4):313-26. PubMed ID: 1486770
[TBL] [Abstract][Full Text] [Related]
22. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
Endrikat J; Jaques MA; Mayerhofer M; Pelissier C; Müller U; Düsterberg B
Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
[TBL] [Abstract][Full Text] [Related]
23. A clinical overview of a new triphasic contraceptive containing gestodene.
Christie T
Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
[TBL] [Abstract][Full Text] [Related]
24. Clinical tolerance of a combined monophasic contraceptive agent containing a low-dose of ethinyloestradiol and gestodene in adolescents.
Leonard F; Gaspard U; Theunissen L
Curr Med Res Opin; 1993; 13(2):78-86. PubMed ID: 8325045
[TBL] [Abstract][Full Text] [Related]
25. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
[TBL] [Abstract][Full Text] [Related]
26. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
27. Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel.
Bassol S; Alvarado A; Celis C; Cravioto MC; Peralta O; Montaño R; Novelli J; Albornoz H; Kesseru E; Soares A; Petracco A; Isaia B; Mendes J; Bahamondes L; de Melo NR; Reyes-Marquez R; Albrecht G
Contraception; 2000 Sep; 62(3):131-5. PubMed ID: 11124360
[TBL] [Abstract][Full Text] [Related]
28. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
Petersen KR; Sidelmann J; Skouby SO; Jespersen J
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):32-8. PubMed ID: 8420344
[TBL] [Abstract][Full Text] [Related]
29. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol).
de Andrade RP
Int J Fertil; 1989 Sep; 34 Suppl():22-30. PubMed ID: 2576253
[TBL] [Abstract][Full Text] [Related]
30. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
31. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
Stone S
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():117-21. PubMed ID: 8260969
[TBL] [Abstract][Full Text] [Related]
32. The effect of desogestrel, gestodene, and other factors on spotting and bleeding.
Rosenberg MJ; Waugh MS; Higgins JE
Contraception; 1996 Feb; 53(2):85-90. PubMed ID: 8838484
[TBL] [Abstract][Full Text] [Related]
33. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
[TBL] [Abstract][Full Text] [Related]
34. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
[TBL] [Abstract][Full Text] [Related]
35. Contraceptive efficacy and safety of a monophasic oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol: United States clinical experience using a "Sunday start" approach.
Notelovitz M
Fertil Steril; 1995 Aug; 64(2):261-6. PubMed ID: 7615100
[TBL] [Abstract][Full Text] [Related]
36. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene.
Fuchs N; Düsterberg B; Weber-Diehl F; Mühe B
Contraception; 1995 Jun; 51(6):335-9. PubMed ID: 7554972
[TBL] [Abstract][Full Text] [Related]
37. [A clinical trial of a monophasic contraceptive preparation containing ethinyl estradiol and desogestrel].
Bilotta P; Favilli S
Akush Ginekol (Mosk); 1992; (8-12):40-3. PubMed ID: 1292360
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
Bilotta P; Favilli S
Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
[TBL] [Abstract][Full Text] [Related]
39. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Daly L; Bonnar J
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):430-7. PubMed ID: 2142580
[TBL] [Abstract][Full Text] [Related]
40. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
Chez RA
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
